Trial Profile
A prospective, multicentric, randomized, open label, parallel group, comparative, two arms, safety, efficacy and pharmacokinetic study of Trastuzumab, (Manufactured by Intas Pharmaceuticals Limited, Biopharma Division, Ahmedabad, India) in comparison with Reference Biologic (Trastuzumab, Marketed by Roche) in the patients with HER2-Overexpressing Metastatic Breast Cancer. - NA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 07 Nov 2016 Status changed from recruiting to completed.
- 01 Sep 2016 New trial record